Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina

NCT ID: NCT00194324

Last Updated: 2011-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2004-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study uses MRI to detect the spread of the Miconozole Nitrate OVULE within the vagina. The effect of moderate amounts of physical activity on the spread will be evaluated, and compared to no physical activity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Health Vulvovaginal Candidiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Miconazole nitrate

Intervention Type DRUG

Magnetic resonance imaging

Intervention Type PROCEDURE

Moderate levels of exercise

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Not at risk for pregnancy
* Willing to abstain from intercourse 24 hours prior to MRI
* Regular menstrual cycles (every 23-38 days)
* At least 10 weeks from most recent pregnancy outcome and had 2 spontaneous menstrual cycles since
* Normal pap smear within previous 12 months
* Negative test for yeast, bacterial vaginosis and trichomonas
* Not allergic to any component of the formulation
* No contraindications to MRI
* Not participated in another investigational trial within 30 days
* No history of condition, or finding on exam, that, in the opinion of the investigator, would make participation unsafe for the volunteer or complicate interpretation of the data
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson

INDUSTRY

Sponsor Role collaborator

University of Pennsylvania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Pennsylvania

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kurt T Barnhart, MD, MSCE

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Pennsylvania Reproductive Research Unit

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RRU010

Identifier Type: -

Identifier Source: secondary_id

708889

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Reducing Vaginal Infections in Women
NCT00170430 COMPLETED PHASE3
ProF-001_Phase IIa
NCT03115073 COMPLETED PHASE2/PHASE3
Voriconazole to Treat Fungal Infections
NCT00001940 COMPLETED PHASE3